Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose
cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…

The recommendations listed in this CPG are, whenever possible, evidence based. An extensive
evidence review was conducted through October 2012, and other selected references …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals’ websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-450
(CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Background A substantial proportion of patients receiving fibrinolytic therapy for myocardial
infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial
infarction has not been established. We investigated the efficacy and safety of ticagrelor, a …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …